Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

237 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-15

Study Completion Date

2018-03-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Compare the Efficacy and Safety of Metformin/Rosuvastatin Combination Therapy With Metformin or Rosuvastatin Monotherapy in Patients With Type 2 Diabetes and Dyslipidemia

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial to Investigate the Pharmacokinetics Drug Interaction Between Metformin and Rosuvastatin

NCT02186483

Hyperlipidemia Diabetes

COMPLETED PHASE1

The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers

NCT02982798

Diabetes Hyperlipidemia

COMPLETED PHASE1

Effect of Combination of Mitiglinide and Metformin on Glycemic Control in Patients With Type 2 Diabetes Mellitus

NCT01037842

Type 2 Diabetes

COMPLETED PHASE3

Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

NCT00279045

Diabetes Mellitus, Type 2

COMPLETED PHASE3

Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes

NCT00568984

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multi-center, Randomized, Double-blind, Phase III clinical trial

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Dyslipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group I

Metformin + Rosuvastatin, Dosing to Type II DM with Dyslipidemia

Group Type EXPERIMENTAL

Metformin + Rosuvastatin

Intervention Type DRUG

Group I: Metformin + Rosuvastatin,

Group II

Metformin + placebo, Dosing to Type II DM with Dyslipidemia

Group Type ACTIVE_COMPARATOR

Metformin + placebo

Intervention Type DRUG

Group II: Metformin + placebo,

Group III

Placebo + Rosuvastatin, Dosing to Type II DM with Dyslipidemia

Group Type ACTIVE_COMPARATOR

placebo + Rosuvastatin

Intervention Type DRUG

Group III: placebo + Rosuvastatin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.